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Immunity induced by the 19-kDa fragment of Plasmodium yoelii merozoite surface protein 1 (MSP119) is
dependent on high titers of specific antibodies present at the time of challenge and a continuing active immune
response postinfection. However, the specificity of the active immune response postinfection has not been
defined. In particular, it is not known whether anti-MSP119 antibodies that arise following infection alone are
sufficient for protection. We developed systems to investigate whether an MSP119-specific antibody response
alone both prechallenge and postchallenge is sufficient for protection. We were able to exclude antibodies with
other specificities, as well as any contribution of MSP119-specific CD4
 T cells acting independent of antibody,
and we concluded that an immune response focused solely on MSP119-specific antibodies is sufficient for
protection. The data imply that the ability of natural infection to boost an MSP119-specific antibody response
should greatly improve vaccine efficacy.
The 19-kDa carboxyl terminus of merozoite surface protein
1 (MSP119) is a leading malaria vaccine candidate (reviewed in
reference 7). Previous studies have shown that protective im-
munity induced by MSP119 is dependent on a high titer of
specific antibodies present at the time of challenge (1, 4,5) and
an active immune response against the parasite of undefined
specificity postinfection (6).
Complete protective immunity induced by MSP119 requires
the participation of both specific antibodies and CD4 T cells.
Previous studies demonstrated that transfer of high-titer anti-
MSP119 antibodies into immunodeficient (SCID, nude, BKO,
CD4 T-cell-depleted) mice delayed parasite growth, but the
mice ultimately developed parasitemia and succumbed to in-
fection (6). In contrast, transfer of antibodies into normal mice
can protect them. It thus appears that an active immune re-
sponse postchallenge that is dependent on B cells and T cells
is critical for MSP119-induced protective immunity (4). Since
certain strains of normal mice that cannot themselves mount
an antibody response to MSP119 (i.e., immunological nonre-
sponders) can nevertheless be passively protected by MSP119-
specific antibodies, it appears that proteins other than MSP119
must be capable of protecting mice. However, the specificity of
this active immune response postinfection has not been de-
fined. In particular, it is not known whether an MSP119-specific
response postinfection is sufficient for protective immunity.
The possibility of a contribution from effector CD4 T cells to
MSP119-induced immunity has not been completely eliminated.
Depletion of CD4 T cells in MSP119-immunized mice can elim-
inate the protective immunity induced by MSP119 vaccination (1,
5). The mechanism by which CD4 T cells contribute to the
protective immunity remains unclear and needs further investi-
gation. A number of CD4 T-cell epitopes on MSP119, including
a dominant epitope recognized by different strains of mice and
referred to as p24, have been identified (13). Adoptive transfer of
T-cell lines specific to p24 into nude mice does not protect the
mice, suggesting that effector T cells may play only a minor role in
protective immunity. However, T cells with other (undefined)
specificities are known to be able to protect mice independent of
antibody (12), and it is possible that MSP119-specific CD4
 T
cells contribute in an ancillary way to immunity and complement
antibody-mediated protection.
In this study, the nature and specificity of the immune re-
sponse that develops following immunization with MSP119 and
parasite challenge were investigated. By using an adoptive
transfer system in which nude mice received p24-specific T
cells and were then immunized with recombinant MSP119 to
restrict the pre- and postchallenge immune responses to
MSP119, the specificity of the active immune response follow-
ing infection was defined. We found that MSP119-specific an-
tibodies alone can control parasitemia postchallenge and that
effector T cells specific to MSP119 play no role in immunity.
MATERIALS AND METHODS
Experimental animals and parasites. Six- to eight-week-old normal and nu/nu
(nude) female BALB/c mice were purchased from Animal Resources Center,
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Willeton, Australia. C57BL/6 -chain knockout (BKO) mice were obtained from
the Centenary Institute of Cancer Medicine and Cell Biology, New South Wales,
Australia, and were bred in our animal house facility. Plasmodium yoelii YM (a
lethal strain) was used.
Recombinant MSP119 protein and antigens. MSP119 of P. yoelii was produced
in Saccharomyces cerevisiae (yMSP119) as described previously (14). A dominant
T-cell epitope on MSP119 (p24; EPTPNAYYEGVFCSSSS) was synthesized as
described previously (13). Ovalbumin (OVA; Sigma, St. Louis, Mo.) was used as
a control antigen.
Immunization and challenge infection. Mice were immunized with phosphate-
buffered saline (PBS) or MSP119 by using the vaccination protocol described
previously (5). Briefly, mice were immunized subcutaneously with PBS or 20 g
of MSP119 in complete Freund’s adjuvant (CFA) (Sigma). The mice were
boosted subcutaneously, intraperitoneally (i.p.), and then i.p. again with the same
dose of antigen in incomplete Freund’s adjuvant (IFA) (Sigma) on days 21, 42,
and 56, respectively. Finally, the mice were boosted i.p. with the same amount of
antigen in PBS on day 63. Ten days after the last immunization, the mice were
challenged intravenously (i.v.) with 104 live P. yoelii YM-parasitized red blood
cells (pRBC). Parasitemia was monitored after infection by microscopic exami-
nation of thin tail blood smears stained with Diff Quick stain (Lab Aids, Narra-
been, Australia).
Adoptive transfer of MSP119 hyperimmune sera. Hyperimmune sera specific
for MSP119 were produced from C57BL/6 mice by using a vaccination protocol
as described above. Recipient mice were injected i.p. with 0.5 ml of these sera or
normal mouse serum (NMS) on days 1, 0, and 1 of challenge infection.
Generation of T-cell lines. T-cell lines specific to p24, OVA, or whole parasite
antigens were generated as described previously (13). Briefly, BALB/c mice were
immunized in the hind footpads with antigen (30 g of peptide, 100 g of OVA,
or 3  107 pRBC) emulsified in CFA. Nine or ten days later, popliteal and
inguinal lymph nodes were removed, and a single-cell suspension was made.
Cells were washed and cultured at a concentration of 2  106 cells/ml in culture
medium (Eagle minimal essential medium [EMEM] supplemented with 50 M
2-mercaptoethanol and 10% heat-inactivated fetal calf serum) in the presence of
10 g of p24 per ml, 100 g of OVA per ml, or 1  106 pRBC per ml. After 4
days of stimulation at 37°C in a 5% CO2 humidified incubator, viable cells were
purified by centrifugation over Ficoll-Paque (Pharmacia Biotech, Uppsala, Swe-
den) and rested at a concentration of 5  105 cells per ml in medium containing
2  106 irradiated syngeneic spleen cells per ml (rest phase). After 10 to 14 days,
the cells were stimulated with specific antigen in the presence of fresh irradiated
normal spleen cells. Repeated cycles of stimulation and resting were performed.
Resting T cells were usually removed to estimate antigen-specific responses by
measuring lymphoproliferation.
Lymphoproliferation assay. Spleen or lymph node T cells were cultured in
EMEM supplemented with 50 M 2-mercaptoethanol and 2% heat-inactivated
normal mouse serum (NMS) at a concentration of 2  106 cells per ml in a
flat-bottom 96-well plate. The cells were cultured with different concentrations of
antigen for 72 h and then were pulse labeled with 0.25 Ci of [3H]thymidine, and
incorporation of radiolabel was estimated 18 to 24 h later by -emission spec-
troscopy.
Cell surface phenotype characterization. Single-cell suspensions of T-cell lines
were stained with phycoerythrin or fluorescein isothiocyanate-conjugated mono-
clonal antibodies specific for mouse CD4, CD3,  T-cell receptor, or  T-cell
receptor (Caltag, Burlingame, Calif.). The cells were incubated for 30 min at 4°C,
washed twice with FACS buffer (0.1% bovine serum albumin, 0.1% sodium
azide, PBS) and resuspended in 250 l of 1% paraformaldehyde. The percentage
of positive cells was measured with a fluorescence-activated cell sorter (Becton
Dickinson) and was analyzed by using CellQuest software (Becton Dickinson).
Bioassay for IFN-, IL-2, and IL-4. Culture supernatants were collected 24,
48, and 72 h after stimulation. Gamma interferon (IFN-), interleukin-2 (IL-2),
and IL-4 activities were determined as described previously (3). IFN- activity
was determined by measuring inhibition of WEHI-279 cell proliferation (11).
IL-2 and IL-4 activities were determined by using the growth-dependent CTLL-2
(2) and CT.4S (8) cell lines, respectively. To demonstrate the specificity of the
cytokine assay with CTLL-2 to detect IL-2 and the specificity of the cytokine
assay with CT.4S to detect IL-4, anti-IL-4 and anti-IL-2, respectively, were added
to the assay mixtures. The concentrations were calculated by using cytokine
standards included in the assays.
Adoptive transfer of T-cell lines. Resting T cells were harvested from cultures.
Viable cells were purified by centrifugation over Ficoll-Paque and washed twice
in EMEM; 2  106 viable cells were injected i.v. into BALB/c nu/nu mice.
Antibody assay. Serum antibody levels were determined by an enzyme-linked
immunosorbent assay (ELISA) as described previously (5).
Western blotting. Crude parasite antigen was prepared by lysing pRBC with
0.01% saponin–PBS at 37°C for 20 min. The pellet was washed twice with PBS
and then sonicated five times for 1 min at 90% output on ice. The supernatant
was collected after centrifugation and dialyzed against PBS. The protein con-
centration was determined with a Bio-Rad protein assay kit (Bio-Rad, Hercules,
Calif.). Crude parasite antigen was separated on a sodium dodecyl sulfate-
polyacrylamide gel and electrophoretically blotted onto nitrocellulose paper,
from which strips were cut and blocked overnight with PBS containing 5% skim
milk. The strips were then incubated with a 1:200 dilution of mouse sera in 0.05%
skim milk–PBS at room temperature for 2 h, washed four times with 0.05%
Tween–PBS, and incubated with a 1:1,000 dilution of horseradish peroxidase-
conjugated goat anti-mouse immunoglobulin (Silenus Lab, Melbourne, Austra-
lia) for 1 h at room temperature. The strips were washed four times, incubated
with substrate (4-chloro-1-naphtol [Sigma]) for 30 min, and then washed four
times with water.
Blood transfer. To examine whether infected mice developed parasitemia at
levels below the level that can be detected by microscopy, 100 to 200 l of whole
blood from individual challenged mice was collected from tail veins in heparin-
ized tubes. The blood was washed twice with sterile PBS, resuspended in 200 l
of PBS, and injected i.p. into naive BALB/c mice. The recipient mice were then
monitored for parasitemia.
Estimation of growth rates. The parasite replication rate in each cycle (g) was
estimated by using the ratio of the number of parasites at the limit of detection
(LOD) to the number of parasites at the first occurrence of parasitemia that was
more than the LOD (day i). In this study the LOD was 0.01% parasitemia or
approximately 500,000 parasites (assuming that each animal has 1 ml of blood).
Since the parasite has a 24-h replication cycle and parasitemia was estimated
every 48 h, the geometric growth equation, (number of parasites on day i) 	 g
(number of parasites on day i  1) 	 g2 (number of parasites on day i  2), was
rearranged to estimate the replication rate:
g  number of parasites on day inumber of parasites on day i 2  number of parasites on day iLOD
The distribution of estimated growth rates was compared for the four experi-
mental groups (PBS immunized plus MSP119 antibodies, PBS immunized plus
NMS, MSP119 immunized plus MSP119 antibodies, and MSP119 immunized plus
NMS) by using the Mann-Whitney U test (for comparing two groups) or the
Kruskal-Wallis test (for comparing more than two groups). When groups were
not significantly different, a grouped growth rate was generated and used to
estimate the starting number of parasites on day 0.
For each animal, the starting number of parasites on day 0 was estimated by
using the first recorded parasitemia greater than the LOD (day i):
starting number of parasites 	
number of parasites on day i
(growth rate)i
The distributions of the estimated starting numbers of parasites were com-
pared for the experimental groups by using either the Mann-Whitney U test or
the Kruskal-Wallis test.
It should be noted that calculating the growth rate by using the LOD and the
first occurrence of parasitemia that is more than the LOD underestimates the
growth rate since the true parasitemia at the first time point is less than the LOD
used in the calculation. Use of these pairs of values was necessary to estimate the
parasite growth rate early in infection, since the data indicated that the growth
rate decreased rapidly as parasitemia increased (due to the decreasing availabil-
ity of uninfected red blood cells). Since the estimated growth rate was likely to
underestimate the true growth rate, the number of parasites on day 0 was
overestimated.
RESULTS
Effector CD4 T cells play no role in MSP119-specific im-
munity. To examine whether effector CD4 T cells play any
role in MSP119-induced immunity, BKO mice were immunized
with PBS or MSP119 by using the protocol that induces com-
plete protection in normal mice (5). Mice also received high-
titer (
6,400,000) MSP119 hyperimmune sera or NMS (0.5
ml/mouse/day) on days 1, 0, and 1 relative to the day of
challenge. Although hyperimmune serum alone cannot protect
BKO mice (5), it can significantly delay the appearance of
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parasites in peripheral blood, suggesting that parasite numbers
are significantly reduced. We could thus ask whether the T-cell
response to MSP119 that develops in BKO mice (5) can control
either a standard inoculum of parasites or a significantly re-
duced inoculum. The mice were challenged i.v. with 1  104 P.
yoelii YM-pRBC on day 0.
Parasite growth rates were estimated as described in Mate-
rials and Methods and are shown in Fig. 1. By extrapolation,
we could also estimate the number of viable parasites present
in the mice immediately after challenge. There was no signif-
icant difference between the two groups of animals immunized
with PBS or MSP119 and which received NMS (P 
 0.8) or
between the immunized groups which received antibody (P 

0.6). However, there was a significant difference in the distri-
bution of the number of starting parasites between animals
which received NMS and animals which received MSP119 an-
tibodies. The median starting parasite loads were 18 parasites
for the immunized animals given immune serum and 429 par-
asites for mice given NMS (P 0.005). Although the estimated
number of viable parasites was far less than the number of
pRBC administered to mice, the day of patency (when para-
sites were first detected by microscopy) was similar to the day
reported previously for mice given 104 parasites (1, 4), suggest-
ing that many parasites die in vitro prior to injection.
All mice that received NMS died within 6 days (Fig. 1A and
B). The anti-MSP119 specific antibodies delayed the patent
parasitemia until day 6 (Fig. 1C and D). Then, the parasitemia
increased and all mice succumbed to infection. There was no
significant difference in the course of infection between the
PBS-immunized and MSP119-immunized groups. The increase
in parasitemia was inversely correlated with clearance of trans-
fused antibodies (Fig. 1E and F). Since the BKO mice had a
C57BL/6 background, C57BL/6 mice immunized with the same
protocol were used as the vaccination control group. MSP119-
immunized C57BL/6 mice showed complete protection with no
patent parasitemia on blood smears (data not shown).
Thus, vaccination of BKO mice cannot provide control
against a normal inoculum, and furthermore, even though the
transferred antibody reduced the median estimated viable par-
asite load at the time of challenge to only 18 parasites, the
immune response to MSP119 that developed in the absence of
antibody was unable to eradicate the parasites.
p24-specific T cells provide help for an MSP119-specific
antibody response. If MSP119-specific effector CD4 T cells are
not involved in immunity, it appears to be very likely that
protection following vaccination must rely on antibody. Since
certain strains of normal mice that cannot themselves mount
an antibody response to MSP119 can nevertheless be passively
protected by MSP119-specific antibodies, it also appears that
proteins other than MSP119 must be capable of protecting
mice and that these arise following challenge (6). We thus
explored whether MSP119-specific antibodies alone, which
arise following infection, can protect mice.
T-cell lines specific to a helper epitope on MSP119 (p24) and
OVA were generated from BALB/c mice by repeated cycles of
stimulation with specific antigens and resting in vitro. Both
T-cell lines expressed CD4 and  T-cell receptors and se-
creted IFN- and IL-2, and no IL-4 was detected by a cytokine-
dependent T-cell assay when the lines were stimulated with the
antigens (p24 or OVA) (Table 1). In addition, the profile of
cytokine production by the T cells generated was confirmed by
a cytokine ELISA and by intracellular cytokine staining (data
not shown).
Nude mice were given 2  106 p24- or OVA-specific T cells.
The mice were then immunized with five doses of MSP119 or
PBS by using the standard vaccination protocol (5). Ten days
after the last immunization, the mice were challenged i.v. with
1  104 P. yoelii YM-pRBC. Naive nude and BALB/c mice
were used as controls. Baseline sera from mice that later re-
ceived p24 T cells and were immunized with MSP119 did not
contain detectable antibodies; however, the antibody titers spe-
cific for MSP119 increased after subsequent boosts (Fig. 2D).
At the time of challenge, most of the p24-specific T-cell-trans-
fused nude mice that were immunized with MSP119 had anti-
body titers greater than 2  106; the only exception was one
mouse which had a lower titer (7  105). These levels were
comparable to the levels of anti-MSP119 antibodies that devel-
oped in MSP119-immunized normal BALB/c mice (Fig. 2F).
No significant level of MSP119-specific antibodies was detected
in other groups (Fig. 2A, B, C, and E). The data demonstrate
that p24-specific helper T cells can provide help for an
MSP119-specific antibody response. The isotypes of anti-
MSP119 specific antibodies in both MSP119-immunized
BALB/c and p24-specific T-cell-transfused nude mice were
predominantly immunoglobulin G1 (IgG1) and IgG2a (data
not shown).
Protective immune response in p24-specific T-cell-trans-
fused nude mice. OVA- and p24-specific T-cell-transfused or
naive nude mice that were immunized with PBS or MSP119
were challenged i.v. with 1  104 P. yoelii YM-pRBC. Immu-
nization with PBS or MSP119 did not induce protection in mice
that received OVA-specific T cells (Fig. 2G and H). These
mice developed parasitemia on day 4 postchallenge and even-
tually succumbed to infection. Mice that received p24-specific
T cells and were then immunized with PBS were also unable to
control parasitemia (Fig. 2I), further confirming the lack of
protective efficacy of MSP119-specific T cells in the absence of
antibody. In contrast, six of seven mice that received p24-
specific T cells and were then immunized with MSP119 showed
complete protection, with no parasites detected in blood
smears (Fig. 2J). One mouse in this group was able to delay
parasite growth until day 7; parasitemia gradually increased to
a peak of 11.67% on day 11, but the mouse was then able to
clear the parasites by day 23. Control nude mice that were
vaccinated with either PBS or MSP119 developed high para-
sitemia and succumbed to infection (data not shown).
BALB/c mice that were immunized with PBS developed
high parasitemia and died within 8 days (Fig. 2K). Four of five
MSP119-immunized BALB/c mice showed complete protec-
tion, and no parasites were detected on blood smears (Fig. 2L).
One mouse in this group was able to suppress parasite growth
until day 8, and then it developed a low level of parasitemia
which peaked at 5.2% on day 14; however, the mouse was able
to clear the parasites by day 20.
Nude or BALB/c mice that had no parasitemia detectable on
blood smears were shown not to harbor parasites on day 11
postchallenge by transferring blood into naive BALB/c re-
porter mice. No parasites were detected in the recipient mice
(data not shown). This indicates that MSP119-immunized
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FIG. 1. (A to D) Parasitemia and anti-MSP119 antibody levels in BKO mice. BKO mice were immunized with PBS (A and C) or MSP119 (B
and D) and were then given NMS (A and B) or anti-MSP119 antibody (Abs) (C and D) on day 1, day 1, and the day of challenge (day 0); they
were then challenged with 1  104 P. yoelii YM-pRBC. Each line represents an individual mouse in each group. (E and F) Levels of transferred
anti-MSP119 antibodies in relation to parasitemia. Sera were diluted 1:4,000 before analysis by ELISA. The parasite growth rates were calculated
as described in Materials and Methods, and the 95% confidence intervals were 2.3 to 18.5 merozoites/schizont for the animals immunized with PBS
and given anti-MSP119 antibodies, 27.6 to 42.6 merozoites/schizont for animals immunized with PBS and given NMS, 5.5 to 14.4 merozoites/
schizont for animals immunized with MSP119 and given anti-MSP119 serum, and 21.3 to 43.9 merozoites/schizont for animals immunized with
MSP119 and given NMS. There was no statistical difference between the growth rates of the two groups of animals given antibodies (P 
 0.95) or
between the growth rates of the two control groups (P 
 0.8). Grouping of the data indicated that there was a significant difference between the
growth rates of antibody recipients and control animals (the means were 10.2 and 33.7 merozoites/schizont for antibody recipients and control
animals, respectively [P  0.01]). The data are the results of one of two independent experiments in which similar findings were obtained. O.D.,
optical density.
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BALB/c and p24 T-cell-transfused nude mice were completely
protected by MSP119 vaccination.
Specificity of antibodies that developed after challenge in-
fection. Sera from nude mice that were given p24-specific T
cells and were then immunized with MSP119 were collected
before and after challenge. The specificities of antibodies that
developed in these mice were then investigated by Western
blotting. Figure 3A shows that sera taken from three represen-
tative mice before challenge and sera taken on days 16 and 24
after challenge recognized only a 19-kDa band on Western
blots. No other antibodies were detected in postchallenge sera
from the mouse that recovered from patent parasitemia (Fig.
3A, lanes 14 and 15). The ability of the antibodies to bind to
the 19-kDa band was eliminated after the sera were preincu-
bated with 100 g of MSP119 for 1 h (lanes 8, 12 and 16).
To demonstrate that the reason that no other bands were
seen on Western blots was not because of either technical
difficulties or because of an inability of nude mice to produce
antibody to other proteins, P. yoelii whole-parasite-specific T
cells were transferred into a group of nude mice. The mice
were infected i.v. with live P. yoelii-pRBC and treated 3 days
later with 0.2 mg of the parasiticidal drug pyrimethamine for
three consecutive days. Thus, the mice received whole-parasite
vaccination. Five weeks later, the mice were challenged i.v.
with 104 P. yoelii-pRBC. All mice that were given whole-par-
asite-specific T cells but not OVA-specific T cells survived a
challenge infection (data not shown). Sera were collected and
were analyzed by Western blotting. Figure 3B shows that these
mice were able to produce antibodies with multiple antigenic
specificities.
DISCUSSION
This study makes a novel contribution to our knowledge of
how immunization with MSP119 leads to protection from ma-
laria. Although MSP119 is one of the leading malaria vaccine
candidates (7), the mechanism by which immunity is induced
following vaccination with MSP119 is not well understood. In
murine models it is known that folding of the antigen is critical
for protection (10) and that antibodies need to be present at
high titers at the time of challenge (1, 4, 5). Depletion of CD4
T cells from immunized mice prior to challenge can prevent an
anamnestic antibody response to MSP119 following challenge
and can also eliminate immunity in a proportion of animals (1,
5).
In this study, we first investigated the role of effector CD4
T cells in MSP119-induced immunity. Previous studies sug-
gested that these cells play little role (5) but could not exclude
the possibility that they play some role. MSP119-immunized
BKO mice were given anti-MSP119 hyperimmune serum. We
expected these high-titer antibodies to significantly reduce the
parasite burden and questioned whether effector T cells could
then clear the few remaining parasites. We estimated that the
antibodies reduced the parasite burden at the time of chal-
lenge by a factor of 24, leaving approximately 18 parasites.
However, the inability of MSP119-immunized BKO mice to
control parasite growth (Fig. 1), even though MSP119-specific
antibodies were administered, strongly suggests that T cells
that develop after MSP119 vaccination cannot contribute to
antibody-independent immunity at all. It is unlikely that the
inability of BKO mice to control parasites was due to a lack of
stimulation of T cells, as we have shown that T lymphocytes
from MSP119-immunized BKO mice respond to MSP119 in
vitro (5). While it could be argued that so few parasites were
unable to activate an immune response, it should be noted that
passively acquired antibodies are able to protect normal mice,
often without detectable parasitemia. Overall, the data suggest
that the loss of protection in our study was a result of a lack of
continuous production of antibodies.
The data from the BKO mouse study and the observation
that immunization of mice with defined CD4 T-cell epitopes
from MSP119 does not induce immunity (13) suggest that im-
munity is due solely to MSP119-specific antibodies present at
the time of challenge and possibly also to a boosting of these
antibodies during challenge. Further studies demonstrated that
the immune response postchallenge is critical since passive
transfer of high-titer serum into mice lacking B or T cells (or
both) cannot prevent mice from succumbing to infection (6).
These data implied that an active antibody response postchal-
lenge was critical, but they did not indicate the antigenic spec-
ificity of the antibodies. Nevertheless, the study showing that
passive transfer of high-titer serum into MSP119-nonresponder
strain normal mice could protect them (6) suggested that an-
tibodies with specificities other than MSP119 can be involved in
protection. It was not known whether one or multiple target
antigens were necessary. To address this issue, we transferred
T cells specific for a single epitope on MSP119 into nude mice
and then immunized the transfused nude mice with MSP119.
Our data show that these mice were protected following infec-
tion. Most importantly, the immune response in these mice was
focused on MSP119 (Fig. 3). The data suggest that a single
antigenic specificity was sufficient to induce protective immu-
TABLE 1. Characteristics of p24- and OVA-specific T-cell linesa
T cells
% of: Cytokine production (U/ml)
Stimulation index of
proliferative response to
specific antigens
CD3-positive
cells
CD4-positive
cells
 T-cell
receptor-positive
cells
 T-cell
receptor-positive
cells
IFN- IL-2 IL-4 100 g/ml 10 g/ml
OVA specific 99.78 99.52 97.00 0.74 4,035 210 1 18.4 NDb
p24 specific 99.36 99.35 98.45 1.11 1,014 134 1 ND 38
a The surface phenotype was characterized by staining with relevant monoclonal antibodies. Cytokine production was analyzed in supernatants collected from T-cell
lines stimulated for 24 h with specific antigen. The concentrations of IFN-, IL-2, and IL-4 were determined by calculating values from a standard curve.
b ND, not done.
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FIG. 2. Anti-MSP119 antibody responses following each immunization (A to F) and parasitemia following challenge infection (G to L). Nude
mice (four to seven mice per group) were transfused with 2  106 OVA-specific T cells (A, B,G, and H) or 2  106 p24-specific T cells (C, D, I,
and J). The mice were then immunized with five doses of PBS (A, C, G, and I) or 20 g of MSP119 (B, D, H, and J), which was followed by i.v.
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nity against blood stage malaria and that MSP119 has suitable
specificity. Thus, MSP119-specific antibodies must be present
at a high titer at the time of challenge, and an active postchal-
lenge MSP119-specific immune response alone is sufficient for
parasite control. Consistent with the results of previous exper-
iments performed with BALB/c normal mice (3), an MSP119-
specific isotype in the nude mice was shown to be IgG1. Of
particular interest was the observation that in our in vivo
model, the nude mice which received Th1 type cells produced
IgG1 antibody. It is likely that IL-4 drives this type of immune
response, but its source is unclear. It may be produced by the
mice themselves and may come from cells of the innate im-
mune system, as suggested by other workers (9).
Vaccination with MSP119 can result in sterile protection
following challenge. The data now demonstrate that antibodies
specific for MSP119 alone are sufficient to eradicate parasites.
However, such antibodies must be produced during challenge.
This is important new information that has relevance for vac-
cine development since it underscores the importance of nat-
ural boosting of the vaccine-induced anti-MSP119 antibody
response by infection. It is possible, for example, that a vaccine
could induce an antibody response as a result of T-cell help
being induced by a nonmalaria carrier protein. Infection would
not be expected to boost such an antibody response. It is
important that the parameters of memory and the potential for
natural boosting be considered in evaluating merozoite surface
protein 1 vaccine candidates and possibly all vaccine candi-
dates based on merozoite surface antigens.
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